Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 4
1967 4
1968 10
1969 8
1970 11
1971 18
1972 9
1973 12
1974 11
1975 23
1976 19
1977 40
1978 33
1979 32
1980 23
1981 41
1982 32
1983 28
1984 38
1985 39
1986 36
1987 47
1988 33
1989 37
1990 36
1991 33
1992 36
1993 49
1994 22
1995 27
1996 37
1997 33
1998 36
1999 33
2000 26
2001 25
2002 31
2003 31
2004 21
2005 28
2006 35
2007 34
2008 44
2009 34
2010 28
2011 38
2012 45
2013 46
2014 44
2015 45
2016 35
2017 49
2018 56
2019 47
2020 42
2021 43
2022 48
2023 36
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

1,749 results

Results by year

Filters applied: . Clear all
Page 1
Future Directions in the Treatment of Osteosarcoma.
Smrke A, Anderson PM, Gulia A, Gennatas S, Huang PH, Jones RL. Smrke A, et al. Cells. 2021 Jan 15;10(1):172. doi: 10.3390/cells10010172. Cells. 2021. PMID: 33467756 Free PMC article. Review.
Osteosarcoma is the most common primary bone sarcoma and is often diagnosed in the 2nd-3rd decades of life. Response to the aggressive and highly toxic neoadjuvant methotrexate-doxorubicin-cisplatin (MAP) chemotherapy schedule is strongly predictive of outcome. ...Predicti …
Osteosarcoma is the most common primary bone sarcoma and is often diagnosed in the 2nd-3rd decades of life. Response to the aggressive and h …
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.
Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Pápai Z, Meyer J, Nadel H, Randall RL, Deffenbaugh C, Nagarajan R, Brennan B, Letson GD, Teot LA, Goorin A, Baumhoer D, Kager L, Werner M, Lau CC, Sundby Hall K, Gelderblom H, Meyers P, Gorlick R, Windhager R, Helmke K, Eriksson M, Hoogerbrugge PM, Schomberg P, Tunn PU, Kühne T, Jürgens H, van den Berg H, Böhling T, Picton S, Renard M, Reichardt P, Gerss J, Butterfass-Bahloul T, Morris C, Hogendoorn PC, Seddon B, Calaminus G, Michelagnoli M, Dhooge C, Sydes MR, Bernstein M; EURAMOS-1 investigators. Bielack SS, et al. J Clin Oncol. 2015 Jul 10;33(20):2279-87. doi: 10.1200/JCO.2014.60.0734. Epub 2015 Jun 1. J Clin Oncol. 2015. PMID: 26033801 Free PMC article. Clinical Trial.
PURPOSE: EURAMOS-1, an international randomized controlled trial, investigated maintenance therapy with pegylated interferon alfa-2b (IFN-alpha-2b) in patients whose osteosarcoma showed good histologic response (good response) to induction chemotherapy. PATIENTS AND …
PURPOSE: EURAMOS-1, an international randomized controlled trial, investigated maintenance therapy with pegylated interferon a …
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort.
Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, Gorlick R, Janeway KA, Ingleby FC, Anninga J, Antal I, Arndt C, Brown KLB, Butterfass-Bahloul T, Calaminus G, Capra M, Dhooge C, Eriksson M, Flanagan AM, Friedel G, Gebhardt MC, Gelderblom H, Goldsby R, Grier HE, Grimer R, Hawkins DS, Hecker-Nolting S, Sundby Hall K, Isakoff MS, Jovic G, Kühne T, Kager L, von Kalle T, Kabickova E, Lang S, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Mayer-Steinacker R, Meyers PA, Nagarajan R, Randall RL, Reichardt P, Renard M, Rechnitzer C, Schwartz CL, Strauss S, Teot L, Timmermann B, Sydes MR, Marina N. Smeland S, et al. Eur J Cancer. 2019 Mar;109:36-50. doi: 10.1016/j.ejca.2018.11.027. Epub 2019 Jan 25. Eur J Cancer. 2019. PMID: 30685685 Free PMC article. Clinical Trial.
A three-drug combination with methotrexate, doxorubicin and cisplatin was defined as standard chemotherapy, and between April 2005 and June 2011, 2260 patients were registered. ...For patients with localised disease at presentation and in complete remission after surgery, …
A three-drug combination with methotrexate, doxorubicin and cisplatin was defined as standard chemotherapy, and between April 2005 an …
Metastatic osteosarcoma.
Daw NC, Billups CA, Rodriguez-Galindo C, McCarville MB, Rao BN, Cain AM, Jenkins JJ, Neel MD, Meyer WH. Daw NC, et al. Cancer. 2006 Jan 15;106(2):403-12. doi: 10.1002/cncr.21626. Cancer. 2006. PMID: 16353204 Free article. Clinical Trial.
The initial study (OS-86) used ifosfamide, cisplatin, doxorubicin, and high-dose methotrexate, and the subsequent study (OS-91) used the same agents at similar doses, but carboplatin was substituted for cisplatin. ...Unilateral lung metastases (P = 0.006), no more than thr …
The initial study (OS-86) used ifosfamide, cisplatin, doxorubicin, and high-dose methotrexate, and the subsequent study (OS-91) used …
An update on chemotherapy for osteosarcoma.
Ferrari S, Serra M. Ferrari S, et al. Expert Opin Pharmacother. 2015;16(18):2727-36. doi: 10.1517/14656566.2015.1102226. Epub 2015 Oct 29. Expert Opin Pharmacother. 2015. PMID: 26512909 Review.
Since then minor innovations have occurred although recent years have offered insights of clinical and scientific relevance. AREAS COVERED: This review focuses on the most recent results of phase 3 and 2 studies. ...EXPERT OPINION: Osteosarcoma is a rare tumor and a …
Since then minor innovations have occurred although recent years have offered insights of clinical and scientific relevance. AREAS CO …
Historical perspective on the introduction and use of chemotherapy for the treatment of osteosarcoma.
Jaffe N. Jaffe N. Adv Exp Med Biol. 2014;804:1-30. doi: 10.1007/978-3-319-04843-7_1. Adv Exp Med Biol. 2014. PMID: 24924166 Review.
The first agents that held promise were doxorubicin and high-dose methotrexate with leucovorin (citrovorin factor) in the mid-1970s. Since then, other agents that can eliminate or cause regression of tumor have been discovered: cis-diamminedichloroplatinum II (cisplatin) a …
The first agents that held promise were doxorubicin and high-dose methotrexate with leucovorin (citrovorin factor) in the mid-1970s. …
Analysis of chemotherapy dosage and dosage intensity and survival outcomes of high-grade osteosarcoma patients younger than 40 years.
Sun L, Li Y, Li H, Zhang J, Li B, Ye Z. Sun L, et al. Clin Ther. 2014 Apr 1;36(4):567-78. doi: 10.1016/j.clinthera.2014.02.018. Epub 2014 Mar 14. Clin Ther. 2014. PMID: 24636527 Review.

The study period ranged from 1976 to 2006. Using univariate analysis, the planned dosage and DI of methotrexate and ifosfamide correlated with better 5-year EFS (P = 0.001 for methotrexate dosage; P = 0.030 for ifosfamide dosage; P < 0.001 for methotrexate

…
The study period ranged from 1976 to 2006. Using univariate analysis, the planned dosage and DI of methotrexate and ifosfamide correl …
Efficacy of methotrexate, doxorubicin, and cisplatin for osteosarcoma: Study protocol for a systematic review of randomized controlled trial.
Tang QX, Wang LC, Wang Y, Gao HD, Hou ZL. Tang QX, et al. Medicine (Baltimore). 2019 Feb;98(6):e14442. doi: 10.1097/MD.0000000000014442. Medicine (Baltimore). 2019. PMID: 30732208 Free PMC article. Review.
BACKGROUND: This systematic review will address the efficacy and safety of methotrexate, doxorubicin, and cisplatin (MAP) for the treatment of patients with osteosarcoma. ...A systematic review and data synthesis will be performed of randomiz …
BACKGROUND: This systematic review will address the efficacy and safety of methotrexate, doxorubicin, and cisplatin (MA …
The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis.
Zhang B, Zhang Y, Li R, Li J, Lu X, Zhang Y. Zhang B, et al. J Orthop Surg Res. 2020 Feb 13;15(1):51. doi: 10.1186/s13018-020-1576-0. J Orthop Surg Res. 2020. PMID: 32054494 Free PMC article. Review.
The network meta-analysis was performed using software R 3.3.2 and STATA version 41.0 after demographic and outcome data extraction. ...In addition, the consistency of direct and indirect evidence was assessed by node splitting. RESULTS: The network meta-a …
The network meta-analysis was performed using software R 3.3.2 and STATA version 41.0 after demographic and outcome data extra …
High-dose methotrexate therapy.
Bell R, Sullivan JR, Moon WJ, Hurley TH. Bell R, et al. Med J Aust. 1977 Feb 19;1(8):247-9. doi: 10.5694/j.1326-5377.1977.tb130665.x. Med J Aust. 1977. PMID: 300460
Eighty-six adults with malignant disease were given high doses of methotrexate with folinic acid rescue, with acceptable toxicity. Protocal violations in two cases led to death. ...
Eighty-six adults with malignant disease were given high doses of methotrexate with folinic acid rescue, with acceptable toxicity. Pr …
1,749 results